James Fox
Director/Board Member at TTP Group Ltd.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Mark Allison | M | 62 | 15 years | |
| Hany Massarany | M | 62 |
Planet Innovation Pty Ltd.
 Planet Innovation Pty Ltd. Medical SpecialtiesHealth Technology Planet Innovation Pty Ltd. is a healthtech innovation and Australian commercialization company that specializes in product development and manufacturing. The private company is based in Box Hill, AU. and has subsidiaries in the United States. It was founded in 2009 by Eduardo Vom, Sam Lanyon, Stuart Elliott, and Troy O'Callaghan, with Stuart Elliott serving as the CEO since its inception. | 10 years |
| Norman John Thompson | M | - |
Altitude Aerospace Interiors Ltd.
 Altitude Aerospace Interiors Ltd. Auto Parts: OEMProducer Manufacturing Altitude Aerospace Interiors Ltd. manufactures, engineers, and designs cabin interiors. The private company is based in Auckland, New Zealand. Altitude Aerospace Interiors was acquired by AIM Aviation Ltd., a subsidiary of the Government of China, from Air New Zealand Ltd. on September 30, 2014. | - |
| Sam Lanyon | M | - |
Planet Innovation Pty Ltd.
Planet Innovation Pty Ltd. Medical SpecialtiesHealth Technology Planet Innovation Pty Ltd. is a healthtech innovation and Australian commercialization company that specializes in product development and manufacturing. The private company is based in Box Hill, AU. and has subsidiaries in the United States. It was founded in 2009 by Eduardo Vom, Sam Lanyon, Stuart Elliott, and Troy O'Callaghan, with Stuart Elliott serving as the CEO since its inception. | 15 years |
| Charles Pizzey | M | - |
Vision Systems Pty Ltd.
 Vision Systems Pty Ltd. Medical SpecialtiesHealth Technology Vision Systems Pty Ltd. develops, manufactures, and distributes technology products and services to the healthcare markets. It produces automated system solutions and vitro diagnostic instruments for cancer detection. The company was founded in 1984 and is headquartered in Mount Waverley, Australia.
Planet Innovation Pty Ltd.
Planet Innovation Pty Ltd. Medical SpecialtiesHealth Technology Planet Innovation Pty Ltd. is a healthtech innovation and Australian commercialization company that specializes in product development and manufacturing. The private company is based in Box Hill, AU. and has subsidiaries in the United States. It was founded in 2009 by Eduardo Vom, Sam Lanyon, Stuart Elliott, and Troy O'Callaghan, with Stuart Elliott serving as the CEO since its inception. | 31 years |
| Keith Alexander Haddow | M | 66 |
TTP Group Ltd.
 TTP Group Ltd. Information Technology ServicesTechnology Services TTP Group Plc engages in the provision of technology and product development services through its subsidiaries. It helps large and small companies to recognize, create and exploit new technologies. The company in October 1987 and is headquartered in Royston, the United Kingdom. | - |
| Robert Ellis | M | 72 |
Dedalus Dh Australia Pty Ltd.
 Dedalus Dh Australia Pty Ltd. Packaged SoftwareTechnology Services Dedalus Dh Australia Pty Ltd. develops software and provides IT solutions for the healthcare industry. It offers medication management, EMR-mobility suite, patient flow, laboratory and national ehealth agenda solutions. The company was founded by Brian L. Cohen in 1982 and is headquartered in Sydney, Australia. | 14 years |
| Troy O'Callaghan | M | - |
Planet Innovation Pty Ltd.
Planet Innovation Pty Ltd. Medical SpecialtiesHealth Technology Planet Innovation Pty Ltd. is a healthtech innovation and Australian commercialization company that specializes in product development and manufacturing. The private company is based in Box Hill, AU. and has subsidiaries in the United States. It was founded in 2009 by Eduardo Vom, Sam Lanyon, Stuart Elliott, and Troy O'Callaghan, with Stuart Elliott serving as the CEO since its inception. | 15 years |
| Stuart Elliott | M | - |
Planet Innovation Pty Ltd.
Planet Innovation Pty Ltd. Medical SpecialtiesHealth Technology Planet Innovation Pty Ltd. is a healthtech innovation and Australian commercialization company that specializes in product development and manufacturing. The private company is based in Box Hill, AU. and has subsidiaries in the United States. It was founded in 2009 by Eduardo Vom, Sam Lanyon, Stuart Elliott, and Troy O'Callaghan, with Stuart Elliott serving as the CEO since its inception. | 15 years |
| Eduardo Vom | M | - |
Planet Innovation Pty Ltd.
Planet Innovation Pty Ltd. Medical SpecialtiesHealth Technology Planet Innovation Pty Ltd. is a healthtech innovation and Australian commercialization company that specializes in product development and manufacturing. The private company is based in Box Hill, AU. and has subsidiaries in the United States. It was founded in 2009 by Eduardo Vom, Sam Lanyon, Stuart Elliott, and Troy O'Callaghan, with Stuart Elliott serving as the CEO since its inception. | 15 years |
| Peter John Taylor | M | 70 |
TTP Group Ltd.
TTP Group Ltd. Information Technology ServicesTechnology Services TTP Group Plc engages in the provision of technology and product development services through its subsidiaries. It helps large and small companies to recognize, create and exploit new technologies. The company in October 1987 and is headquartered in Royston, the United Kingdom. | 20 years |
| Kiim Lim | F | - | 18 years | |
| Samuel Charles William Hyde | M | 51 |
TTP Group Ltd.
TTP Group Ltd. Information Technology ServicesTechnology Services TTP Group Plc engages in the provision of technology and product development services through its subsidiaries. It helps large and small companies to recognize, create and exploit new technologies. The company in October 1987 and is headquartered in Royston, the United Kingdom. | - |
| Jing Guo | F | 42 |
Altitude Aerospace Interiors Ltd.
Altitude Aerospace Interiors Ltd. Auto Parts: OEMProducer Manufacturing Altitude Aerospace Interiors Ltd. manufactures, engineers, and designs cabin interiors. The private company is based in Auckland, New Zealand. Altitude Aerospace Interiors was acquired by AIM Aviation Ltd., a subsidiary of the Government of China, from Air New Zealand Ltd. on September 30, 2014. | 5 years |
| Stephen Francis Jones | M | - |
Altitude Aerospace Interiors Ltd.
Altitude Aerospace Interiors Ltd. Auto Parts: OEMProducer Manufacturing Altitude Aerospace Interiors Ltd. manufactures, engineers, and designs cabin interiors. The private company is based in Auckland, New Zealand. Altitude Aerospace Interiors was acquired by AIM Aviation Ltd., a subsidiary of the Government of China, from Air New Zealand Ltd. on September 30, 2014. | - |
| Alan Maderazo | M | - | 5 years | |
| Jaspal Sanghera | M | 70 |
TTP Group Ltd.
TTP Group Ltd. Information Technology ServicesTechnology Services TTP Group Plc engages in the provision of technology and product development services through its subsidiaries. It helps large and small companies to recognize, create and exploit new technologies. The company in October 1987 and is headquartered in Royston, the United Kingdom. | - |
| Susan MacLeman | F | - |
Planet Innovation Pty Ltd.
Planet Innovation Pty Ltd. Medical SpecialtiesHealth Technology Planet Innovation Pty Ltd. is a healthtech innovation and Australian commercialization company that specializes in product development and manufacturing. The private company is based in Box Hill, AU. and has subsidiaries in the United States. It was founded in 2009 by Eduardo Vom, Sam Lanyon, Stuart Elliott, and Troy O'Callaghan, with Stuart Elliott serving as the CEO since its inception. | - |
| Bruce Resnick | M | - | 3 years | |
| Vanessa Wallace | F | 59 |
Multiple Sclerosis Research Australia Ltd.
| - |
| Geoff Cumming | M | - |
Multiple Sclerosis Research Australia Ltd.
| - |
| Adam D. Dakin | M | - |
Multiple Sclerosis Research Australia Ltd.
| - |
| Peter Day | M | 73 |
Multiple Sclerosis Research Australia Ltd.
| - |
| Robert Hubbard | M | 64 |
Multiple Sclerosis Research Australia Ltd.
| - |
| Sean Johnston | M | - | 3 years | |
| Colin David Wall | M | 74 |
TTP Group Ltd.
TTP Group Ltd. Information Technology ServicesTechnology Services TTP Group Plc engages in the provision of technology and product development services through its subsidiaries. It helps large and small companies to recognize, create and exploit new technologies. The company in October 1987 and is headquartered in Royston, the United Kingdom. | - |
| Jonathan Ling | M | 69 |
Planet Innovation Pty Ltd.
Planet Innovation Pty Ltd. Medical SpecialtiesHealth Technology Planet Innovation Pty Ltd. is a healthtech innovation and Australian commercialization company that specializes in product development and manufacturing. The private company is based in Box Hill, AU. and has subsidiaries in the United States. It was founded in 2009 by Eduardo Vom, Sam Lanyon, Stuart Elliott, and Troy O'Callaghan, with Stuart Elliott serving as the CEO since its inception. | - |
| Vanessa Stoddart | F | - |
Altitude Aerospace Interiors Ltd.
Altitude Aerospace Interiors Ltd. Auto Parts: OEMProducer Manufacturing Altitude Aerospace Interiors Ltd. manufactures, engineers, and designs cabin interiors. The private company is based in Auckland, New Zealand. Altitude Aerospace Interiors was acquired by AIM Aviation Ltd., a subsidiary of the Government of China, from Air New Zealand Ltd. on September 30, 2014. | - |
| Robert McDonald | M | - |
Altitude Aerospace Interiors Ltd.
Altitude Aerospace Interiors Ltd. Auto Parts: OEMProducer Manufacturing Altitude Aerospace Interiors Ltd. manufactures, engineers, and designs cabin interiors. The private company is based in Auckland, New Zealand. Altitude Aerospace Interiors was acquired by AIM Aviation Ltd., a subsidiary of the Government of China, from Air New Zealand Ltd. on September 30, 2014. | - |
| James McCrone | M | - |
TTP Group Ltd.
TTP Group Ltd. Information Technology ServicesTechnology Services TTP Group Plc engages in the provision of technology and product development services through its subsidiaries. It helps large and small companies to recognize, create and exploit new technologies. The company in October 1987 and is headquartered in Royston, the United Kingdom. | 21 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Russell H. Plumb | M | 65 |
Aviragen Therapeutics, Inc.
 Aviragen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aviragen Therapeutics, Inc. engages in the discovery and development of direct-acting antivirals to treat infections. Its product candidates include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics; BTA074, a topical antiviral treatment for genital warts caused by human papillomavirus types 6 & 11; BTA585, an oral fusion protein inhibitor for the treatment of RSV-A and RSV-B infections; and laninamivir octanoate, a one-time, inhaled treatment for influenza A and B infections. The company was founded on November 8, 2012 and is headquartered in Alpharetta, GA. | - |
| Scott Mendel | M | 57 | - | |
| Richard James Hill | M | 77 |
Aviragen Therapeutics, Inc.
Aviragen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aviragen Therapeutics, Inc. engages in the discovery and development of direct-acting antivirals to treat infections. Its product candidates include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics; BTA074, a topical antiviral treatment for genital warts caused by human papillomavirus types 6 & 11; BTA585, an oral fusion protein inhibitor for the treatment of RSV-A and RSV-B infections; and laninamivir octanoate, a one-time, inhaled treatment for influenza A and B infections. The company was founded on November 8, 2012 and is headquartered in Alpharetta, GA. | 6 years |
| Joseph Patti | M | 60 |
Aviragen Therapeutics, Inc.
Aviragen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aviragen Therapeutics, Inc. engages in the discovery and development of direct-acting antivirals to treat infections. Its product candidates include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics; BTA074, a topical antiviral treatment for genital warts caused by human papillomavirus types 6 & 11; BTA585, an oral fusion protein inhibitor for the treatment of RSV-A and RSV-B infections; and laninamivir octanoate, a one-time, inhaled treatment for influenza A and B infections. The company was founded on November 8, 2012 and is headquartered in Alpharetta, GA. | 6 years |
| Jeffery Errington | M | 68 |
Aviragen Therapeutics, Inc.
Aviragen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aviragen Therapeutics, Inc. engages in the discovery and development of direct-acting antivirals to treat infections. Its product candidates include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics; BTA074, a topical antiviral treatment for genital warts caused by human papillomavirus types 6 & 11; BTA585, an oral fusion protein inhibitor for the treatment of RSV-A and RSV-B infections; and laninamivir octanoate, a one-time, inhaled treatment for influenza A and B infections. The company was founded on November 8, 2012 and is headquartered in Alpharetta, GA. | 3 years |
| James Hutchinson Ranck | M | 76 | 10 years | |
| Peter J. Azzarello | M | 53 |
Aviragen Therapeutics, Inc.
Aviragen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aviragen Therapeutics, Inc. engages in the discovery and development of direct-acting antivirals to treat infections. Its product candidates include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics; BTA074, a topical antiviral treatment for genital warts caused by human papillomavirus types 6 & 11; BTA585, an oral fusion protein inhibitor for the treatment of RSV-A and RSV-B infections; and laninamivir octanoate, a one-time, inhaled treatment for influenza A and B infections. The company was founded on November 8, 2012 and is headquartered in Alpharetta, GA. | 3 years |
| John Leonard Palmer | M | 76 | 13 years | |
| Geoffrey F. Cox | M | 80 |
Aviragen Therapeutics, Inc.
Aviragen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aviragen Therapeutics, Inc. engages in the discovery and development of direct-acting antivirals to treat infections. Its product candidates include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics; BTA074, a topical antiviral treatment for genital warts caused by human papillomavirus types 6 & 11; BTA585, an oral fusion protein inhibitor for the treatment of RSV-A and RSV-B infections; and laninamivir octanoate, a one-time, inhaled treatment for influenza A and B infections. The company was founded on November 8, 2012 and is headquartered in Alpharetta, GA. | 12 years |
| Kevin O'Boyle | M | 68 | 11 years | |
| Damian T. Lismore | M | 64 | 8 years | |
| Antony Carter | M | 65 | 9 years | |
| Ian MacDonald | M | 70 | 6 years | |
| Malcolm Jackman | M | 71 | 5 years | |
| Tyler Jensen | M | - | 9 years | |
| Daryl Jay Faulkner | M | 75 | 11 years | |
| Michael Dougherty | M | 66 |
Aviragen Therapeutics, Inc.
Aviragen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aviragen Therapeutics, Inc. engages in the discovery and development of direct-acting antivirals to treat infections. Its product candidates include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics; BTA074, a topical antiviral treatment for genital warts caused by human papillomavirus types 6 & 11; BTA585, an oral fusion protein inhibitor for the treatment of RSV-A and RSV-B infections; and laninamivir octanoate, a one-time, inhaled treatment for influenza A and B infections. The company was founded on November 8, 2012 and is headquartered in Alpharetta, GA. | 5 years |
| Eric J. Stier | M | 48 | 9 years | |
| Robert Jan Jager | M | - | 8 years | |
| Paul Jonathon Bingham | M | - | 9 years | |
| Michael Dunne | M | 64 |
Aviragen Therapeutics, Inc.
Aviragen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aviragen Therapeutics, Inc. engages in the discovery and development of direct-acting antivirals to treat infections. Its product candidates include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics; BTA074, a topical antiviral treatment for genital warts caused by human papillomavirus types 6 & 11; BTA585, an oral fusion protein inhibitor for the treatment of RSV-A and RSV-B infections; and laninamivir octanoate, a one-time, inhaled treatment for influenza A and B infections. The company was founded on November 8, 2012 and is headquartered in Alpharetta, GA. | - |
| Janice Dawson | F | 70 | 10 years | |
| Christopher M. Luxon | M | 53 | 8 years | |
| Lisa Giles | F | 65 | 6 years | |
| Raymond Ridge | M | - | 8 years | |
| Brett Morris | M | - | 9 years | |
| Johnny Ek | M | 48 | 8 years | |
| Scott Alexander O'Brien | M | - | 9 years | |
| Robert Harvey Wylie | M | 73 | 3 years | |
| Michael S. Kagnoff | M | 55 | 6 years | |
| Raymond George Grigg | M | 82 | 8 years | |
| Paul E. Ross | M | 50 | 1 years | |
| Armando Anido | M | 66 |
Aviragen Therapeutics, Inc.
Aviragen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aviragen Therapeutics, Inc. engages in the discovery and development of direct-acting antivirals to treat infections. Its product candidates include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics; BTA074, a topical antiviral treatment for genital warts caused by human papillomavirus types 6 & 11; BTA585, an oral fusion protein inhibitor for the treatment of RSV-A and RSV-B infections; and laninamivir octanoate, a one-time, inhaled treatment for influenza A and B infections. The company was founded on November 8, 2012 and is headquartered in Alpharetta, GA. | 3 years |
| Matthew Robert Cohen | M | 52 | - | |
| Jennifer Anne Williams | F | 50 | 9 years | |
| Anne VanLent | F | 76 |
Aviragen Therapeutics, Inc.
Aviragen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aviragen Therapeutics, Inc. engages in the discovery and development of direct-acting antivirals to treat infections. Its product candidates include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics; BTA074, a topical antiviral treatment for genital warts caused by human papillomavirus types 6 & 11; BTA585, an oral fusion protein inhibitor for the treatment of RSV-A and RSV-B infections; and laninamivir octanoate, a one-time, inhaled treatment for influenza A and B infections. The company was founded on November 8, 2012 and is headquartered in Alpharetta, GA. | - |
| Anthoni Salim | M | 75 | 6 years | |
| John P. Richard | M | 66 |
Aviragen Therapeutics, Inc.
Aviragen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aviragen Therapeutics, Inc. engages in the discovery and development of direct-acting antivirals to treat infections. Its product candidates include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics; BTA074, a topical antiviral treatment for genital warts caused by human papillomavirus types 6 & 11; BTA585, an oral fusion protein inhibitor for the treatment of RSV-A and RSV-B infections; and laninamivir octanoate, a one-time, inhaled treatment for influenza A and B infections. The company was founded on November 8, 2012 and is headquartered in Alpharetta, GA. | - |
| Christopher M. Gleeson | M | 73 | 4 years | |
| Linda Jenkinson | F | - | 7 years | |
| Stephen Worland | M | 66 | 3 years | |
| Jonathan Mason | M | 65 | 9 years | |
| John Bellano | M | 56 | - | |
| Grant F. Latta | M | - | 5 years | |
| Sarah Hollis Winkler | F | 49 | 4 years | |
| Brian Mitchell | M | 59 | 4 years | |
| Jodie King | F | - | 8 years | |
| Nooshin Hussainy | M | 66 | 1 years | |
| Glen Robert Sowry | M | - | 10 years | |
| Mark Harvey | M | 69 | 5 years | |
| Lorraine N. Murphy | F | - | 3 years | |
| Abe Chohan | M | - | 1 years | |
| Ingo Chakravarty | M | - | 3 years | |
| Jeffrey Hawkins | M | 46 | 5 years | |
| S. Gerlach | M | 78 | 14 years | |
| Sue Pierce | F | - | - | |
| Shaun C. Hughes | M | - | 3 years | |
| Ross Edwin Mallett | M | - | 2 years | |
| Walter Hubert Johnson | M | - | - | |
| Julia Raue | F | - | 8 years | |
| Charles Ernest Bright | M | 78 | - | |
| Maxwell George Ormsby | M | 74 | 16 years | |
| Robert Tanti | M | - | 2 years | |
| Ronald Powell Carter | M | - | - | |
| Jane Freeman | F | - | 9 years | |
| John McDonald | M | - | 9 years | |
| Peter Chapman E. Cook | M | 77 |
Aviragen Therapeutics, Inc.
Aviragen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aviragen Therapeutics, Inc. engages in the discovery and development of direct-acting antivirals to treat infections. Its product candidates include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics; BTA074, a topical antiviral treatment for genital warts caused by human papillomavirus types 6 & 11; BTA585, an oral fusion protein inhibitor for the treatment of RSV-A and RSV-B infections; and laninamivir octanoate, a one-time, inhaled treatment for influenza A and B infections. The company was founded on November 8, 2012 and is headquartered in Alpharetta, GA. | 1 years |
| Raafat E. F. Fahim | M | 70 |
Aviragen Therapeutics, Inc.
Aviragen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aviragen Therapeutics, Inc. engages in the discovery and development of direct-acting antivirals to treat infections. Its product candidates include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics; BTA074, a topical antiviral treatment for genital warts caused by human papillomavirus types 6 & 11; BTA585, an oral fusion protein inhibitor for the treatment of RSV-A and RSV-B infections; and laninamivir octanoate, a one-time, inhaled treatment for influenza A and B infections. The company was founded on November 8, 2012 and is headquartered in Alpharetta, GA. | 1 years |
| Paul Ronald Bell | M | 76 |
Aviragen Therapeutics, Inc.
Aviragen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aviragen Therapeutics, Inc. engages in the discovery and development of direct-acting antivirals to treat infections. Its product candidates include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics; BTA074, a topical antiviral treatment for genital warts caused by human papillomavirus types 6 & 11; BTA585, an oral fusion protein inhibitor for the treatment of RSV-A and RSV-B infections; and laninamivir octanoate, a one-time, inhaled treatment for influenza A and B infections. The company was founded on November 8, 2012 and is headquartered in Alpharetta, GA. | 1 years |
| Bick Sellers | F | 52 | 1 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 41 | 41.00% |
| Australia | 36 | 36.00% |
| New Zealand | 21 | 21.00% |
| United Kingdom | 6 | 6.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- James Fox
- Personal Network
